Examining the Role of Frontline BTKi Monotherapy in CLL

Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).

EP. 1: Approved BTKi Frontline Treatments for CLL

March 29th 2021

Jennifer R. Brown, MD, PhD, highlights newly FDA approved Bruton’s tyrosine kinase inhibitor (BTKi) monotherapy therapies for the treatment of CLL (chronic lymphocytic leukemia).

EP. 2: Tolerability of Ibrutinib, Zanubrutinib, and Acalabrutinib

March 29th 2021

Citing results from recent trials, Jennifer R. Brown, MD, PhD, compares patient tolerability levels of ibrutinib, zanubrutinib, and acalabrutinib.

EP. 3: Advice for Ibrutinib-Intolerant Patients

March 29th 2021

Jennifer R. Brown, MD, PhD, suggests alternative treatments for patients who experience severe adverse-events from ibrutinib.

EP. 4: Unmet Needs in Frontline Treatment of CLL

March 29th 2021

The shortcomings physicians face in combatting CLL (chronic lymphocytic leukemia) are discussed, in addition to what the high-level updates from the ELEVATE-RR press release may reveal regarding future treatments for CLL.